Company: VCYT
Filing Date: 2025-08-07
Form Type: 10-Q
Source: 0001384101-25-000110
Chunk: 12

Company: VERACYTE, INC.
Filing Date: 2025-08-07
Form: 10-Q
Item: Part I, Item 1
Chunk 12
---
,670,853 1,655,961 Accumulated deficit(437,916)(443,983)Accumulated other comprehensive loss(11,959)(36,090)Total stockholders’ equity1,221,057 1,175,966 Total liabilities and stockholders’ equity$1,344,104 $1,300,035  

The accompanying notes are an integral part of these condensed consolidated financial statements.

1

Table of Contents

VERACYTE, INC.

 Condensed Consolidated Statements of Operations

 (Unaudited)

 (In thousands, except share and per share amounts)

 Three Months Ended June 30,Six Months Ended June 30, 2025202420252024Revenue:    Testing revenue$122,263 $106,970 $229,572 $197,273 Product revenue3,598 3,906 7,178 7,443 Biopharmaceutical and other revenue4,303 3,552 7,887 6,556 Total revenue130,164 114,428 244,637 211,272 Cost of revenue:Cost of testing revenue32,407 27,920 60,667 53,899 Cost of product revenue1,749 1,874 3,171 4,518 Cost of biopharmaceutical and other revenue3,572 3,812 6,270 6,650 Intangible asset amortization - cost of revenue2,667 2,909 5,252 5,824 Total cost of revenue40,395 36,515 75,360 70,891 Gross profit89,769 77,913 169,277 140,381 Operating expenses:Research and development16,264 16,465 33,984 32,430 Selling and marketing25,316 24,216 49,770 47,998 General and administrative32,331 31,745 66,139 57,955 Impairment of assets20,505 — 20,505 429 Intangible asset amortization - operating expenses621 881 1,243 1,619 Total operating expenses95,037 73,307 171,641 140,431 Income (loss) from operations(5,268)4,606 (2,364)(50)Other income,